A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Bendamustine; Rituximab
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Therapeutic Use
- Sponsors Seattle Genetics
- 30 Oct 2017 Status changed from active, no longer recruiting to completed.
- 30 May 2017 Status changed from recruiting to active, no longer recruiting.
- 19 May 2017 This trial has been completed in Spain as per European Clinical Trials Database record.